Inspired by the tetrachromatic vision of butterflies, researchers have developed an artificial optoelectronic synapse using monolayer tungsten disulfide (WS₂). This device can simultaneously sense and process both ultraviolet and visible light, mimicking key brain functions like learning and memory with an ultralow energy cost of 2.28 aJ per event. An 8 × 8 synaptic array was built to demonstrate high-fidelity image sensing, memory, and preprocessing, boosting recognition accuracy of complex color images to over 98%. This work paves the way for next-generation machine vision systems with ultraviolet-visible spectral intelligence.

The United States still leads China in the quality and commercial reach of its biomedical science but is losing the race to translate scientific discoveries into cures. New analyses from the Cure Innovation Index, released today ahead of Cure's session on U.S.-China biomedical competitiveness at the BIO International Convention in San Diego, find that without immediate renewed investment and policy changes, the U.S. scientific edge will not hold. “America’s challenge is no longer discovery alone. The emerging battleground is translation, the speed and efficiency with which scientific breakthroughs move from the laboratory into development, commercialization, and patient impact," said Seema Kumar, CEO of Cure, the premier healthcare innovation ecosystem headquartered in New York City. If the United States wants to stay ahead, the answer isn't to out-publish China. It's to fix the translational bottlenecks with renewed funding, especially for early translational work, modernized clinical trial infrastructure, and stronger bridges between academic research and industry.